Sapropterin

Evidence Level: L5

Predicted Indications: 2

Sapropterin

Pharmacist Assessment Report

Sapropterin: From Phenylketonuria to Disorder of Tyrosine Metabolism

One-Sentence Summary

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), originally used to treat phenylketonuria (PKU) and other disorders of phenylalanine metabolism. The TxGNN model predicts it may be effective for disorder of tyrosine metabolism, but no clinical trials are registered for this term, and the 15 publications retrieved concern PKU, the original indication, rather than a new one.

Quick Overview

Item	Content
Original Indication	Phenylketonuria; disorder of phenylalanine metabolism (approved indication text is not listed for the ARTG entry)
Predicted New Indication	Disorder of tyrosine metabolism
TxGNN Prediction Score	0.9989
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, sapropterin is a synthetic analogue of tetrahydrobiopterin (BH4), the natural cofactor of phenylalanine hydroxylase. This enzyme converts phenylalanine to tyrosine. Its efficacy in BH4-responsive PKU is established.

The link to “disorder of tyrosine metabolism” is indirect. The retrieved literature is about PKU, not primary tyrosine disorders such as tyrosinemia. The ontology appears to group PKU under tyrosine and aromatic amino acid metabolism, so the high score probably reflects the existing indication rather than a genuinely new one. This prediction should be treated with caution.

Other predictions in the list point the same way:

BH4-responsive hyperphenylalaninemia/PKU and hyperphenylalaninemia due to BH4 deficiency are effectively on-label or very close to the original indication. They are clinical standard care rather than true repurposing.
Lower-ranked predictions such as teratogenic Pierre Robin syndrome have no identifiable mechanistic link. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. This prediction has no trial or literature support.

Clinical Trial Evidence

Currently no related clinical trials registered for disorder of tyrosine metabolism.

For context, the KAMPER registry (NCT01016392) is an observational study of long-term sapropterin safety in PKU. It is not evidence for the predicted indication.

Literature Evidence

None of the publications below addresses primary tyrosine metabolism disorders. They concern PKU and are shown for context. No RCT of sapropterin in the predicted indication was identified.

PMID	Year	Type	Journal	Key Findings
29025426	2017	Guideline	Orphanet J Rare Dis	European guidelines on PKU diagnosis and treatment
34784942	2021	Consensus statement	Orphanet J Rare Dis	Italian consensus on PKU management and pharmacological treatment
39237321	2025	Long-term safety study	J Inherit Metab Dis	KAMPER registry final results: long-term safety of sapropterin in 576 participants with PAH deficiency
35899555	2022	Guideline/Consensus	Turk J Pediatr	Expert recommendations on PKU diagnosis, treatment and follow-up in Turkey
20738029	2010	Review	Prescrire Int	Sapropterin helps only a minority of PKU patients
42123950	2026	Review	Nutrients	Nutritional and therapeutic strategies in paediatric PKU
30359206	2020	Review	Nutr Neurosci	Dietary therapeutic approaches in PKU
20123474	2010	Review	Mol Genet Metab	Psychosocial issues and outcomes in maternal PKU
34654619	2021	Registry cohort	Mol Genet Metab	Natural history of PKU in the NBS-PKU Connect registry
26653793	2016	Preclinical (mouse)	Mol Genet Metab	High-dose sapropterin improved monoamine neurotransmitter turnover in murine PKU

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
10086W	Kuvan	Tablet (soluble) containing sapropterin dihydrochloride 100 mg (oral)	Not listed in the data compiled for this report

Safety Considerations

Contraindications (knowledge graph, not label text): neutropenia and agranulocytosis are recorded as contraindicated disease associations.
Drug Interactions: 21 interactions are recorded, all Moderate. Main groups:
- Vasodilators and nitrates: nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, nitroprusside, nesiritide, hydralazine, minoxidil (oral and topical), alprostadil
- PDE5 inhibitors: sildenafil, tadalafil, vardenafil
- Folate-pathway antagonists: methotrexate, pemetrexed, pralatrexate, trimetrexate, trimethoprim, pyrimethamine, proguanil
- Levodopa

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted new indication has no registered trials and no specific literature. The high score appears to reflect the existing PKU indication rather than a true new use. The closely related BH4-responsive PKU and BH4-deficiency hyperphenylalaninemia are better handled as on-label or established-practice uses than as repurposing candidates.

To proceed, the following is needed:

Clarification of whether “disorder of tyrosine metabolism” refers to a primary tyrosine disorder (such as tyrosinemia) or is an ontology artefact of PKU
Mechanism of action data, which were unavailable for this report
TGA Product Information (warnings, contraindications and approved indication text) for the Kuvan ARTG entry
Reclassification of BH4-responsive PKU and BH4-deficiency hyperphenylalaninemia as on-label indications
Preclinical or clinical evidence specific to the predicted indication, if it is pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.